(Q38383457)

English

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

scientific article published on 15 December 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial (English)

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Vincent Chung

1

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Shannon McDonough

2

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Philip A Philip

3

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Dana Cardin

4

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Andrea Wang-Gillam

5

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Laifong Hui

6

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Mohamedtaki A Tejani

7

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Tara E Seery

8

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Irene A Dy

9

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Tareq Al Baghdadi

10

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Andrew E Hendifar

11

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

L Austin Doyle

12

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Andrew M Lowy

13

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Katherine A Guthrie

14

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Charles D Blanke

15

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Howard S Hochster

16

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2017

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

3

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

4

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

516-522

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotini

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Oncogenic KRAS signalling in pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

23 June 2018

Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

31 August 2018

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

31 August 2018

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

31 August 2018

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5665683

31 August 2018

Identifiers

10.1001/JAMAONCOL.2016.5383

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

release_sqwnwfpt5rcuhhn3lmrnosc27q

1 reference

https://api.fatcat.wiki/v0/release/sqwnwfpt5rcuhhn3lmrnosc27q

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5665683

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38383457&oldid=1837115472"